Crisil Ratings has revised its outlook on the long-term bank facilities and non-convertible debentures of Metropolis Healthcare Ltd (MHL) to ‘positive’ from ‘stable’, while reaffirming its rating at ‘Crisil AA-‘.
The rating agency also reaffirmed its short-term bank facility rating at ‘Crisil A1+’, according to a note from Crisil Ratings. Crisil said the outlook revision reflects the expected improvement in organic revenue growth, profitability, and cash accruals, along with a meaningful turnaround in its recent acquisition, Core Diagnostics Pvt Ltd.
Higher utilisation of the expanded laboratory network, a favourable test mix, and better profitability at Core Diagnostics are expected to support healthy operating margins over the medium term, the agency noted.
According to the rating agency, MHL’s revenue increased 24 per cent to Rs 1,646 crore in FY26, driven by higher patient volumes and specialised diagnostic and wellness tests under the ‘TruHealth’ brand.
Revenue growth continu
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.